Overall, the small molecule inhibitors appeared to effectively target activated mTOR in all cell lines, but its active downstream protein p70S6K was not consistently affected by treatment in CML-10c2 and 17CM98 (Fig. 7). Here, MTOR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.